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Abstract
Background:  The microenvironment surrounding cells can exert multiple effects on their
biological responses. In particular the extracellular matrix surrounding cells can profoundly
influence their behavior. It has been shown that the extracellular matrix composition in tumors is
vastly different than that found in normal tissue with increased amounts of certain matrices such as
collagen I. It has been previously demonstrated that VEGF stimulation of endothelial cells growing
on type I collagen results in the induction of bcl-2 expression and enhanced endothelial cell survival.
We sought to investigate whether this increased endothelial cell survival resulted in the failure of
angiostatic molecules to inhibit angiogenesis.
Results: We now demonstrate that VEGF-induced survival on collagen I impairs the ability of three
known angiostatic molecules, TSP-1, IP-10 and endostatin to inhibit endothelial cell proliferation.
Apoptosis of endothelial cells, growing on collagen I, induced by TSP-1 and IP-10 was also inhibited
following VEGF stimulation. In contrast, endostatin induced apoptosis in these same cells. Further
analysis determined that endostatin did not decrease the expression of bcl-2 nor did it increase
activation of caspase-3 in the presence of VEGF. Alternatively, it appeared that in the presence of
VEGF, endostatin induced the activation of caspase-8 in endothelial cells grown on collagen I.
Furthermore, only endostatin had the ability to inhibit VEGF-induced sprout formation in collagen
I gels.
Conclusion: These data suggest that TSP-1, IP-10 and endostatin inhibit endothelial cells via
different mechanisms and that only endostatin is effective in inhibiting angiogenic activities in the
presence of collagen I. Our results suggest that the efficacy of angiostatic treatments may be
impaired depending on the context of the extracellular matrix within the tumor environment and
thus could impede the efficacy of angiostatic therapies.
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Background
The growth of tumors beyond 1 mm3 is dependent on the
induction of angiogenesis, defined as the growth of new
blood vessels from preexisting vasculature [1]. The process
of angiogenesis is regulated by a number of promoters
(angiogenic) and inhibitors (angiostatic), and it is the bal-
ance of expression of these opposing molecules that ulti-
mately dictates whether or not angiogenesis proceeds.
There are a number of endogenous angiostatic inhibitors
that have been actively investigated including throm-
bospondin, interferon-inducible protein 10 (IP-10) and
endostatin. Thrombospondin (TSP) was initially identi-
fied as a human platelet derived protein [2] that played a
key role in platelet aggregation [3,4]. It was subsequently
shown to modulate the biological responses of endothe-
lial cells [5,6], induce apoptosis of endothelial cells via a
caspase-3 dependent mechanism [7-9] and inhibit patho-
logical angiogenesis [10-13]. IP-10 is a CXC chemokine
that is secreted by a variety of different cell types in
response to interferon stimulation [14]. In addition to
being a T-cell chemoattractant [15,16], IP-10 has been
shown to be an inhibitor of angiogenesis [17-19] and
tumor growth in vivo [19-21]. Endostatin is the 20 kDa C-
terminal cleavage product of collagen XVIII that has been
shown to have a number of anti-angiogenic properties
including inhibition of endothelial cell proliferation [22]
and migration [23,24], induction of endothelial cell
apoptosis [25], and inhibition of tumor growth in vivo
[22,26-28]. Although these angiostatic molecules have
been shown to be efficacious in pre-clinical models, their
success in clinical trials has been more limited. Part of this
may be due to the fact that very little is understood about
the mechanisms by which these molecules exert their bio-
logical effects and how their efficacy might be altered by
different tumor microenvironments.
The extracellular matrix (ECM) composition in tumors is
vastly different than that found in its normal tissue coun-
terparts. Certain ECM proteins such as collagen I,
fibronectin and tenascin C are increased, while the base-
ment membrane proteins collagen IV and laminin are
decreased in neoplastic as compared to normal breast tis-
sue [29,30]. Previous data suggested that stimulation of
human dermal microvascular endothelial cells (HDMEC)
grown on collagen I with vascular endothelial growth fac-
tor (VEGF) resulted in the increased survival of these cells
by a mechanism involving the upregulation of bcl-2 [31].
It has also been shown that increased endothelial cell sur-
vival following overexpression of bcl-2 was associated
with enhanced tumorigenesis in a xenograft model of
human tumorigenesis [32]. These observations suggested
that increased endothelial cell survival might be modu-
lated by extracellular matrix components such as collagen
I, and may contribute to the progression of tumor growth
and metastasis as a result of enhanced angiogenic poten-
tial within these tumors. Furthermore, this increased sur-
vival may render the endothelial cells more resistant to the
inhibitory effects of certain angiostatic molecules, thus
limiting their efficacy in certain tumor microenviron-
ments. As collagen I is found to be overexpressed in tumor
versus normal tissue of the breast [29,30], and is itself a
substrate for attachment of integrins that can profoundly
influence endothelial function [33-37], we therefore
examined the ability of three known angiostatic mole-
cules, TSP-1, IP-10 and endostatin to inhibit endothelial
cell proliferation, induce endothelial cell apoptosis on
both plastic and collagen I coated surfaces in vitro and to
inhibit VEGF-induced endothelial cell tube formation in
collagen I gels in vitro. We found that although TSP-1 and
IP-10 could inhibit endothelial cell proliferation and
induce apoptosis when HDMEC were cultured on plastic
tissue culture dishes, their ability to inhibit these proc-
esses was impaired following culture of HDMEC on colla-
gen I. We observed similar results when cells were exposed
to endostatin in that it inhibited proliferation of HDMEC
cultured on plastic, but failed to inhibit proliferation of
HDMEC grown on collagen I. In contrast to the results
observed with TSP-1 and IP-10, we found that endostatin
retained the ability to induce apoptosis of HDMEC even
in the presence of collagen I. Furthermore, only endosta-
tin could inhibit the formation of VEGF-induced sprouts
on collagen I gels in vitro, while TSP-1 and IP-10 remained
ineffective in this model system. These data suggest that
the context of the tumor matrix microenvironment may
modulate the inhibitory activity of angiostatic molecules
and this may have significant impact on the ability of
these molecules to function as anti-angiogenic therapeu-
tics clinically in certain tumor types.
Results
Growth on collagen I impairs the ability of TSP-1, IP-10 
and endostatin to inhibit endothelial cell proliferation
There is a significant body of literature demonstrating that
the matrix microenvironment within tumors can be vastly
different than that found in the normal tissue counter-
parts [29,30]. Furthermore, there is increasing evidence
that "tumor-associated" ECM proteins may enhance the
proliferation or survival of endothelial cells. Thus, tumor
microenvironments may create a pro-angiogenic sur-
rounding that impairs the ability of angiostatic molecules
to inhibit endothelial cell growth and survival. We sought
to determine if the angiostatic molecules TSP-1, IP-10 and
endostatin could mediate the same inhibitory effects in
endothelial cells when cells were cultured on plastic or on
collagen I coated dishes. Collagen I was chosen as a
"tumor-associated" ECM protein as its overexpression has
been documented in a number of tumor types, and previ-
ous data suggested that growth of HDMEC on collagen I
followed by stimulation with the angiogenic factor VEGF
led to an increase in bcl-2 expression and enhanced sur-BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
Page 3 of 20
(page number not for citation purposes)
Growth on tumor-associated matrices impairs the ability of TSP-1, IP-10, and endostatin to inhibit endothelial cell proliferation Figure 1
Growth on tumor-associated matrices impairs the ability of TSP-1, IP-10, and endostatin to inhibit endothelial 
cell proliferation. HDMEC were seeded onto plastic or dishes coated with either collagen I, laminin or tenascin C, starved 
and then stimulated with either 50 ng/ml VEGF alone or in combination with 10, 50 or 250 ng/ml TSP-1 (panel A), 16, 80 or 
400 ng/ml IP-10 (panel B) or 20, 100 or 500 ng/ml recombinant endostatin (panel C) for 72 h. Adherent cells were harvested by 
trypsinization or collagenase treatment (in the case of collagen I coated dishes) and direct cell counts were determined by 
counting using a Coulter Counter. All bars represent the mean and standard error of triplicate dishes from three independent 
experiments (n = 9). Within each experiment all samples were normalized to VEGF-induced proliferation and statistical signifi-
cance (* = p < 0.05, ** = p < 0.001) was determined using unpaired t-tests as compared to VEGF.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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Growth on collagen I impairs HDMEC proliferation as measured by BrdU incorporation Figure 2
Growth on collagen I impairs HDMEC proliferation as measured by BrdU incorporation. HDMEC were seeded 
onto plastic or dishes coated with collagen I, starved and then stimulated with 50 ng/ml VEGF either alone or in combination 
with 10, 50 or 250 ng/ml TSP-1 (panel A), 16, 80 or 400 ng/ml IP-10 (panel B) or 100, 500 or 2500 ng/ml recombinant endosta-
tin (panel C) for 48 h. BrdU labeling mixture was then added and the cells were incubated overnight at which time incorpo-
rated BrdU was quantitated using the BrdU Cell Proliferation ELISA (Roche). All bars represent the mean and standard error 
of triplicate samples. All samples were normalized to VEGF-induced BrdU incorporation and statistical significance (* = p < 
0.05) was determined using unpaired t-tests as compared to VEGF.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
Page 5 of 20
(page number not for citation purposes)
vival of endothelial cells [31]. As these results suggested
an increase in the survival potential of endothelial cells
when cultured on collagen I, we initially investigated
whether various angiostatic molecules could inhibit the
proliferation of endothelial cells when cultured on tissue
culture treated plastic dishes or collagen I coated dishes.
Cells were starved overnight and then stimulated with 50
ng/ml VEGF (determined to be the optimal stimulatory
dose of VEGF, data not shown) in combination with vari-
ous doses of each inhibitor, and 72 h post-stimulation,
cells were collected by trypsinization or collagenase treat-
ment and the total number of cells per well was counted
using a Coulter Counter. We observed a dose-dependent
decrease in VEGF-induced HDMEC proliferation follow-
ing addition of TSP-1 (Figure 1A), IP-10 (Figure 1B) and
endostatin (Figure 1C) when cells were cultured on plas-
tic. In contrast, all three angiostatic molecules failed to
inhibit VEGF-induced proliferation when HDMEC were
cultured on collagen I as a substrate (Figure 1). These
results suggested that the ability of the various angiostatic
molecules to inhibit VEGF-induced endothelial cell pro-
liferation was impaired by growth of these cells on the
matrix collagen I. As further confirmation, we examined
the ability of the inhibitors to function following growth
of HDMEC on the normal basement membrane ECM
laminin, or on the tumor-associated ECM tenascin C. In
these cases we saw statistically significant inhibition of
cell proliferation by all three inhibitors when HDMEC
were cultured on laminin while HDMEC were resistant to
the inhibitory effects of the inhibitors following culture
on tenascin C (Figure 1). These results suggest that ECM
proteins associated with tumor growth, such as collagen I
and tenascin C, enhance endothelial cell survival and
impart a resistance to anti-angiostatic molecules.
We examined whether or not the apparent inhibition of
proliferation as measured by direct cell counts was as a
result of inhibition of cellular proliferation and replica-
tion or as a result of increased apoptosis of cells. To
address this issue, we directly measured DNA replication
by BrdU-incorporation assays. Cells were plated in 96-
well microtiter plates, starved overnight in MCDB 131
supplemented with 1% fetal bovine serum (FBS), and
then stimulated with VEGF either alone or in combina-
tion with various doses of TSP-1, IP-10 or endostatin.
BrdU labeling mixture was then added 48 h post-stimula-
tion and cells were incubated overnight. The amount of
incorporated BrdU was then determined using the cell
proliferation BrdU ELISA according to the manufacturer's
directions. As was seen previously using direct cell counts,
we saw statistically significant dose-dependent decreases
in VEGF-induced endothelial cell proliferation as meas-
ured by BrdU incorporation following treatment with
TSP-1 (Figure 2A) and IP-10 (Figure 2B). We also
observed a trend in the reduction of BrdU incorporation
following treatment with endostatin (Figure 2C), however
this did not reach statistical significance. As seen previ-
ously, following growth of endothelial cells on collagen I,
all three molecules were unable to inhibit VEGF-induced
proliferation of HDMEC (Figure 2). These data suggest
that one of the main mechanisms of inhibition of angio-
genesis by TSP-1 and IP-10 is inhibition of endothelial
cell proliferation, and that this mechanism is impaired by
growth of cells on collagen I.
Collagen I impairs endothelial cell apoptosis induced by 
TSP-1 and IP-10, but not by endostatin
Many angiostatic molecules have been shown to induce
apoptosis of endothelial cells and this has been proposed
as one of the main mechanisms by which they inhibit
angiogenesis [7-9]. Since we observed that growth of
HDMEC on the tumor-associated matrices collagen I and
tenascin C impaired the ability of the anti-angiogenic
molecules to inhibit VEGF-induced proliferation, we next
examined whether growth on collagen I influenced the
ability of the angiostatic molecules to induce apoptosis of
endothelial cells, by examining the proportion of cells in
sub-G1 following staining with propidium iodide as a
measure of apoptotic cells. For both HDMEC grown on
plastic or collagen I, we observed a statistically significant
reduction in the number of apoptotic cells following treat-
ment with VEGF (Figure 3), thus demonstrating its ability
to enhance survival of endothelial cells as has been previ-
ously documented. It should be noted that unstimulated
HDMEC have a high level of apoptosis following 62 h in
culture without media changes. This is a result of serum
deprivation that is overcome by the addition of VEGF to
the culture media in the same time frame. Similar to our
results with HDMEC proliferation, we found that TSP-1
could partially overcome the protective effects of VEGF
and induced a statistically significant induction of apop-
tosis when cells were cultured on plastic (Figure 3A). In
contrast, when HDMEC were cultured on collagen I and
treated with VEGF in combination with TSP-1, we
observed only a small but statistically insignificant
increase in apoptosis (Figure 3A) suggesting that TSP-1
was ineffective at inducing apoptosis of endothelial cells
in the presence of collagen I. Similar results were observed
following treatment of HDMEC with IP-10, where we
observed statistically significant induction of apoptosis
using 80 ng/ml of IP-10 when cells were cultured on plas-
tic and stimulated with VEGF, and the failure of IP-10 to
induce significant apoptosis when cells were cultured on
collagen I in the presence of VEGF (Figure 3B). Surpris-
ingly, we observed that endostatin significantly induced
apoptosis of VEGF-stimulated HDMEC regardless of
whether they were cultured on plastic or collagen I as a
substrate (Figure 3C). These data suggest that even though
all three of the inhibitors tested in these experiments have
the capacity to induce endothelial cell apoptosis, theyBMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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Growth on collagen I impairs the ability of TSP-1 and IP-10, but not endostatin to induce apoptosis of HDMEC Figure 3
Growth on collagen I impairs the ability of TSP-1 and IP-10, but not endostatin to induce apoptosis of HDMEC. 
HDMEC were seeded onto plastic or collagen I coated tissue culture dishes, monolayers were washed to remove nonadherent 
cells, and subsequently adherent cells were stimulated with either 50 ng/ml VEGF alone or in combination with 10, 50 or 250 
ng/ml TSP-1 (panel A), 16, 80 or 400 ng/ml IP-10 (panel B) or 100, 500 or 2500 ng/ml recombinant endostatin (panel C) for 60 
h. Non-adherent and adherent cells were then collected, washed twice with PBS, and permeabilized in 70% ethanol for a mini-
mum of 24 h prior to staining with propidium iodide. The percentage of apoptotic cells was determined following identification 
of the subG1 population of cells using FACS analysis. The adherent and nonadherent populations of unstimulated cells were 
included as a control for the basal level of apoptosis of HDMEC (unstimulated-all) and an adherent-only population of unstim-
ulated cells was included to demonstrate the surviving fraction of untreated HDMEC (unstim-adherent). Cells treated with 50 
nM of actinomycin D were included as a positive control for apoptosis. All samples were normalized to the levels of apoptosis 
observed following stimulation with 50 ng/ml VEGF alone. Bars are representative of the mean and standard error of duplicate 
dishes from three independent experiments (n = 6). Statistical significance was determined following analysis using unpaired t-
tests as compared to VEGF (* = p < 0.05).BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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HDMEC treated with TSP-1 and IP-10, but not endostatin show decreases in bcl-2 expression that is inhibited by concomitant  VEGF stimulation Figure 4
HDMEC treated with TSP-1 and IP-10, but not endostatin show decreases in bcl-2 expression that is inhibited 
by concomitant VEGF stimulation. HDMEC were seeded on either plastic or collagen I coated tissue culture dishes, and 
following removal of non-adherent cells by washing, were stimulated with either 50 ng/ml VEGF alone or in combination with 
10, 50 or 250 ng/ml TSP-1 (panel A), 16, 80 or 400 ng/ml IP-10 (panel B), or 100, 500 or 2500 ng/ml recombinant endostatin 
(panel C) for 48 h. Cells were collected by trypsinization or collagenase treatment and total protein lysates were generated. 
Western blots for bcl-2 were performed as described in the methods section. Blots were stripped and reprobed for tubulin as 
a loading control.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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likely do so through different mechanisms that may or
may not be affected by the substrate upon which the cells
are cultured. Taken together with our data regarding BrdU
incorporation, these data suggest that endostatin has
greater effects on apoptosis of endothelial cells as
opposed to their proliferation.
The pro-apoptotic activity of endostatin is independent of 
bcl-2 expression
To further elucidate the mechanism by which the angi-
ostatic molecules induced apoptosis, and whether these
mechanisms were affected by the presence of collagen I,
we examined the ability of angiostatic molecules to mod-
ulate the levels of the anti-apoptotic protein bcl-2 which
we had previously found to be upregulated in HDMEC on
collagen I following VEGF treatment [31], and the activa-
tion of caspase-3 as one of the main mediators of apopto-
sis in endothelial cells. HDMEC cultured on either plastic
or collagen I substrates were stimulated with increasing
concentrations of TSP-1, IP-10 or endostatin, alone or in
combination with VEGF and total protein lysates were
generated. Initially a time course was performed and it
was determined that changes in the expression of the pro-
teins of interest were maximal at 48 h post-stimulation
(data not shown). As seen previously, we observed that
VEGF stimulation of HDMEC on collagen I induced an
increase in the level of bcl-2 protein as compared to
unstimulated controls (Figure 4, right hand panels, lanes
1 and 2). A similar increase in bcl-2 levels was not
observed following VEGF-stimulation of HDMEC cul-
tured on plastic dishes (Figure 4, left hand panels, lanes 1
and 2). In fact, when total protein loading is taken into
consideration, it appeared that the levels of bcl-2 in
HDMEC grown on plastic dishes did not change follow-
ing treatment with any of the angiostatic molecules either
alone or in combination with VEGF (Figure 4, left hand
panels). In contrast to the results observed following cul-
ture on plastic, we observed a dose-dependent decrease in
the expression of bcl-2 following treatment with TSP-1
alone (Figure 4A, right hand panel, lanes 3, 5 and 7 as
compared to lane 1) or IP-10 alone (Figure 4B, right hand
panel, lanes 3, 5 and 7 as compared to lane 1) as com-
pared to unstimulated HDMEC grown on collagen I. This
decrease in bcl-2 expression in HDMEC grown on colla-
gen I was also apparent for TSP-1 (Figure 4A right hand
panel, lanes 4, 6 and 8 as compared to lane 2) and IP-10
(Figure 4B right hand panel, lanes 4, 6 and 8 as compared
to lane 2) treatments in combination with VEGF, but only
when the highest doses of angiostatic molecules were
used. The observed decrease in bcl-2 expression could
account for the small increases in endothelial cell apopto-
sis noted in HDMEC grown on collagen I following stim-
ulation with TSP-1 or IP-10 (Figure 3A,B). With respect to
stimulation of HDMEC on collagen I with endostatin,
there was a slight decrease in bcl-2 expression following
treatment with 100 ng/ml endostatin in combination
with VEGF (Figure 4C, right hand panel, lane 4 as com-
pared to lane 2) when HDMEC were grown on collagen I,
however, no dose-dependent decrease in bcl-2 expression
was observed on either plastic (Figure 4C, left hand panel)
or collagen I (Figure 4C, right hand panel) in response to
endostatin treatment. Thus, it is unlikely that changes in
bcl-2 expression are the cause of the increase in apoptosis
of HDMEC observed in response to endostatin treatment
on either of these substrates at the higher doses of inhibi-
tor. We also probed for bax expression levels in these same
samples and observed that there was no change in bax
protein regardless of the treatment used or upon which
matrix the HDMEC were cultured (data not shown). Thus
it would appear that VEGF induces increased survival of
HDMEC on collagen I in part as a result of its ability to
upregulate bcl-2. Moreover, the slight decreases in bcl-2
expression observed following treatment with TSP-1 or IP-
10 in combination with VEGF are not sufficient to over-
come this increased survival and fail to induce significant
endothelial cell apoptosis when HDMEC are cultured on
collagen I. In contrast, the ability of endostatin to over-
come the VEGF-induced HDMEC survival on collagen I
appeared to be independent of the levels of bcl-2 expres-
sion.
Endostatin-induced endothelial cell apoptosis is 
independent of caspase-3 activation
The angiostatic molecules used in these studies demon-
strated some capacity to induce apoptosis when HDMEC
were cultured on plastic; however, only endostatin
appeared able to induce apoptosis of HDMEC cultured on
collagen I. To determine potential mechanisms of induc-
tion of apoptosis, we examined whether or not the angi-
ostatic molecules in question led to the activation of
caspase-3 when cells were cultured on either plastic or col-
lagen I as a substrate. At high doses of TSP-1, we saw a
decrease in procaspase-3, indicating cleavage of this pro-
tein into active caspase-3, following treatment of HDMEC
cultured on plastic with 50 ng/ml TSP-1 as compared to
unstimulated controls (Figure 5A, left hand panel, lane 5
as compared to lane 1). For all other treatment conditions
of HDMEC cultured on plastic there did not appear to be
cleavage or activation of procaspase-3, hence no reduction
in the amount of procaspase-3 detected by western blot
(Figure 5A, left hand panel). When HDMEC cultured on
plastic were treated with various doses of IP-10 (Figure 5B,
left hand panel) or endostatin (Figure 5C, left hand panel)
alone or in combination with VEGF, we observed essen-
tially no change in the levels of procaspase-3 suggesting
that there is no active caspase-3 produced following
HDMEC stimulation with these inhibitors. We observed
no change in procaspase-3 levels when HDMEC were cul-
tured on collagen I and stimulated with TSP-1 alone as
compared to unstimulated controls (Figure 5A, right handBMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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HDMEC treated with TSP-1 and IP-10, but not endostatin show slight decreases in procaspase-3 expression Figure 5
HDMEC treated with TSP-1 and IP-10, but not endostatin show slight decreases in procaspase-3 expression. 
HDMEC were seeded on either plastic or collagen I coated tissue culture dishes, and following removal of non-adherent cells 
by washing, were stimulated with either 50 ng/ml VEGF alone or in combination with 10, 50 or 250 ng/ml TSP-1 (panel A), 16, 
80 or 400 ng/ml IP-10 (panel B), or 100, 500 or 2500 ng/ml recombinant endostatin (panel C) for 48 h. Cells were collected by 
trypsinization or collagenase treatment and total protein lysates were generated. Western blots for procaspase-3 were per-
formed as described in materials and methods. Blots were stripped and reprobed for tubulin as a loading control.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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Activation of caspase-3 is abrogated by VEGF stimulation in HDMEC cultured on collagen I Figure 6
Activation of caspase-3 is abrogated by VEGF stimulation in HDMEC cultured on collagen I. HDMEC were 
seeded on either plastic or collagen I coated tissue culture dishes, and following removal of non-adherent cells by washing, 
were stimulated with either 50 ng/ml VEGF alone or in combination with 10, 50 or 250 ng/ml TSP-1 (panel A), 16, 80 or 400 
ng/ml IP-10 (panel B), or 100, 500 or 2500 ng/ml recombinant endostatin (panel C) for 48 h. Cells were collected following col-
lagenase treatment and counted. Cell pellets were lysed in appropriate volumes of lysis buffer to generate extracts containing 
equal number of cells per unit volume. A fluorometric based assay for caspase-3 activity was performed using Ac-DEVD-AMC 
as a substrate as described in the methods section. Bars are representative of the mean and standard error for triplicate sam-
ples. The experiment was performed three independent times with similar results. Statistical significance was determined using 
unpaired t-tests as compared to unstimulated samples or to VEGF stimulated samples for TSP-1, IP-10 or endostatin alone or 
in combination with VEGF respectively (* = p < 0.05).BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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panel, lanes 3, 5 and 7 as compared to lane 1). We did
however observe decreases in procaspase-3 with increas-
ing concentrations of TSP-1 when HDMEC grown on col-
lagen I were treated with TSP-1 in combination with
VEGF, indicating that at higher doses of TSP-1, activation
of caspase-3 following procaspase-3 cleavage occurs even
in the presence of collagen I (Figure 5A, right hand panel,
lanes 4, 6 and 8 as compared to lane 2). It would appear
that under certain conditions, VEGF prevents the cleavage
of procaspase-3 into active caspase-3 to some extent, how-
ever we did not consistently observe this phenomenon. It
should also be noted that unstimulated HDMEC on plas-
tic or collagen I have a fairly high apoptotic rate with
approximately 40–50% of unstimulated cells being apop-
totic after 62 h of culture (data not shown). Therefore, the
baseline level of procapase-3 seen in the unstimulated
condition inherently reflects a certain level of caspase-3
activation. Even though we detected a decrease in procas-
pase-3 indicating that caspase-3 had been activated and
proteolytically processed following treatment of HDMEC
Endostatin does not induce cleavage of caspase-3 into its active forms Figure 7
Endostatin does not induce cleavage of caspase-3 into its active forms. HDMEC were seeded on either plastic or col-
lagen I coated tissue culture dishes, and following removal of non-adherent cells by washing, were stimulated with either 50 ng/
ml VEGF alone or in combination with 100, 500 or 2500 ng/ml recombinant endostatin for 48 h. Cells were collected by 
trypsinization or collagenase treatment and total protein lysates were generated. Western blots for active caspase-3 were per-
formed as described in the methods section.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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Endostatin induces the activity of caspase-8 Figure 8
Endostatin induces the activity of caspase-8. A) HDMEC were seeded on tissue culture dishes, and following removal of 
non-adherent cells by washing, were stimulated with either 50 ng/ml VEGF alone or in combination with 100, 500 or 2500 ng/
ml recombinant endostatin for 48 h. Cells were collected and total protein lysates were generated. Western blots for procas-
pase-8 were performed as described in materials and methods. Blots were stripped and reprobed for tubulin as a loading con-
trol. B) HDMEC were seeded on tissue culture dishes, and following removal of non-adherent cells by washing, were 
stimulated with either regular media (unstimulated), or media containing 100, 500, or 2500 ng/ml endostatin, in the presence 
or absence of 50 ng/ml VEGF, or stimulated with anti-fas antibody as a positive control for caspase-8 activation. Cells were col-
lected by trypsinization and cell pellets stored at -80°C. Subsequently, pellets were lysed and total protein concentration was 
determined. Caspase-8 activity was then detected using a commercially available fluorometric detection kit (Sigma, Oakville, 
ON) as described in the methods section. An additional sample was included using the anti-fas treated cell lysate in the pres-
ence of specific caspase-8 inhibitors to demonstrate the specificity of the assay.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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cultured on collagen I with TSP-1 and VEGF as compared
to treatment with VEGF alone (Figure 5A, right hand
panel), we surprisingly did not observe significant
increases in the apoptosis of TSP-1 and VEGF treated cells
on collagen I. It is possible that the degree of procaspase-
3 cleavage was insufficient to induce significant apoptosis
in this system or that growth on collagen I induces a block
in the apoptotic pathway downstream of caspase-3. Alter-
natively, it is possible that measurement of the reduction
in procaspase-3 levels is not indicative of the generation of
active caspase-3. In contrast to TSP-1, we saw very little
changes in the levels of procaspase-3 following stimula-
tion of HDMEC on collagen I with either IP-10 (Figure 5B,
right hand panel) or endostatin (Figure 5C, right hand
panel) alone or in combination with VEGF.
As decreases in procaspase-3 levels may not necessarily be
reflective of caspase-3 activation, we performed addi-
tional experiments to detect active caspase-3 using a fluor-
ometric assay based on the cleavage of the caspase-3
substrate Ac-DEVD-AMC. As with previous experiments,
cells were cultured on plastic or collagen I and stimulated
with the indicated doses of TSP-1, IP-10 or endostatin in
the presence of 50 ng/ml VEGF. Although none of the
conditions reached statistical significance, we observed a
trend for increased caspase-3 activity in HDMEC treated
with TSP-1 (Figure 6A), IP-10 (Figure 6B), or endostatin
(Figure 6C) in combination with VEGF following culture
on plastic. We did not observe these same increases in cas-
pase-3 activity following treatment of HDMEC with TSP-
1, IP-10 or endostatin in combination with VEGF when
cells were cultured on collagen I (Fig. 6). These results
support the results obtained by western blot analysis and
suggest that when HDMEC are cultured on collagen I acti-
vation of caspase-3 is inhibited and cells do not undergo
apoptosis in response to inhibitors as a result.
Since we observed the induction of apoptosis of HDMEC
following treatment by endostatin when cells were cul-
tured on collagen I, we were surprised to find that caspase-
3 did not appear to be activated by endostatin. As both
detection of procaspase forms and the fluorometric activ-
ity assays are known to be variable, we performed western
blots using an antibody to the active form of caspase-3,
which readily detects the 17 and 12 kDa cleavage prod-
ucts, in an attempt to confirm our previous findings. We
found that when cultured on plastic, a slight increase in
the active form of caspase-3 could be observed following
treatment with 100 ng/ml of endostatin alone as com-
pared to unstimulated cells (Fig. 7, top panel, lane 3 as
compared to lane 1). However, in the presence of VEGF,
there was no detectable activation of caspase-3 at any of
the doses of endostatin tested (Fig. 7, top panel, lanes 4, 6
and 8 as compared to lane 2). Similarly, although some
active caspase-3 could be detected following endostatin
treatment of HDMEC cultured on collagen I, this activity
was not increased as compared to that observed in the
unstimulated HDMEC (Fig. 7, bottom panel, lanes 3, 5
and 7 as compared to lane 1). In support of our previous
data, we observed no increases in the levels of the active
forms of caspase-3 following stimulation of HDMEC on
collagen I with VEGF in combination with endostatin at
any of the doses tested (Fig. 7, bottom panel, lanes 4, 6
and 8 as compared to lane 2). The lack of active caspase-3
cleavage products following treatment with VEGF also
supports the contention that VEGF can increase the sur-
vival potential of endothelial cells by reducing their apop-
totic rate. Taken together, our data suggests that
endostatin is the sole angiostatic molecule tested in this
system that retains the ability to induce apoptosis of
endothelial cells following growth on collagen I. Surpris-
ingly however, the endostatin-induced apoptosis appears
to occur via a caspase-3 independent mechanism that is
insensitive to signals mediated through attachment of
cells to collagen I.
Endostatin, but not TSP-1 or IP-10, can inhibit VEGF-induced  tube-formation on collagen I gels Figure 9
Endostatin, but not TSP-1 or IP-10, can inhibit VEGF-
induced tube-formation on collagen I gels. HDMEC 
were seeded on collagen I gels, and following removal of 
non-adherent cells by washing, were stimulated with media 
alone (unstimulated) or media containing 50 ng/ml VEGF 
alone or in combination with 50 ng/ml TSP-1, 80 ng/ml IP-10 
or 500 ng/ml endostatin. Cells were counted daily and media 
was replenished every second day. Graph is representative of 
the mean and standard error of the number of sprouts 
counted in 12 random fields of view at 100× magnification in 
triplicate dishes (n = 24). Statistical significance was deter-
mined at day 12 using unpaired t-tests as compared to VEGF 
treated cells (* = p < 0.05).BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
Page 14 of 20
(page number not for citation purposes)
Endostatin induces the activation of caspase-8 in HDMEC 
grown on collagen I
It has been demonstrated that apoptosis of cells may
occur through activation of "death receptors" that prima-
rily mediate their effects via activation of caspase-8
(recently reviewed by [38]). As caspase-8 can also be acti-
vated by other mechanisms independent of death recep-
tor activation [39,40], we sought to determine whether
the mechanism of endostatin-induced apoptosis of
endothelial cells was caspase-8 dependent. We thus exam-
ined the expression of caspase-8 following treatment of
cells with various doses of endostatin alone or in combi-
nation with 50 ng/ml VEGF. We could detect a reduction
in procaspase-8, suggesting cleavage into its active forms
in HDMEC treated with 2500 ng/ml of endostatin alone
or in combination with 50 ng/ml VEGF (Fig. 8A, lane 7 as
compared to lane 1, and lane 8 as compared to lane 2).
Endothelial cells that were not allowed to adhere to sub-
stratum and are known to undergo apoptosis via a fas-
mediated mechanism in this situation were used as a pos-
itive control for procaspase-8 cleavage and activation (Fig.
8A, lane 9). We further confirmed these results following
the detection of active caspase-8 using a fluorometric
assay based on cleavage of the substrate Ac-IETD-AMC.
HDMEC were stimulated with the various concentrations
of endostatin alone or in combination with VEGF as indi-
cated. As a positive control, an activating antibody to fas
receptor was added to cultured cell supernatants to induce
cleavage of caspase-8 (Fig. 8B, closed diamonds). To dem-
onstrate the specificity of the activity in the assay, cells
were also treated with anti-fas antibody in the presence of
a specific caspase-8 inhibitor (Fig. 8B, open diamonds).
Active caspase-8 could only be detected in HDMEC
treated with 2500 ng/ml of endostatin alone or in combi-
nation with 50 ng/ml VEGF (Fig. 8B, open and closed
upright triangles respectively). We did not detect active
caspase-8 following stimulation with the lower doses of
endostatin either by western blot or activity assays. These
data suggest that endostatin mediates endothelial cell
apoptosis in part by the activation of caspase-8, at least at
higher doses. It is possible that endostatin induces apop-
tosis at the lower doses tested by activating caspase-8 at a
level that is below our threshold of detection, or that at
lower doses endostatin induces apoptosis via a caspase-8
independent pathway.
Endostatin but not TSP-1 or IP-10 inhibits VEGF-induced 
HDMEC sprout-formation on collagen I gels
An additional manner by which angiogenesis might be
inhibited is via the prevention of the organization of
endothelial cells into vessel-like structures. To determine
the ability of TSP, IP-10 and endostatin to inhibit this
process we utilized an in vitro tube-formation assay that
uses collagen I gels as a substrate. In this system, HDMEC
seeded on fibrillar collagen I gels do not spontaneously
form tube-like structures, but only do so after stimulation
with angiogenic factors such as VEGF. Cells will initially
align with one another and begin to extend themselves
into an initial "sprouting" cell; and then following 8–12
days in culture, they will form multicellular tube struc-
tures with lumen. HDMEC were seeded on collagen I gels
and were then stimulated with 50 ng/ml VEGF alone or in
combination with either 50 ng/ml TSP-1, 80 ng/ml IP-10
or 500 ng/ml endostatin. The number of multicellular
tube-like structures was counted daily for a period of 12
days. We found that neither TSP-1 nor IP-10 could inhibit
the VEGF-induced tube formation in this assay system
(Fig. 9, triangles and diamonds respectively). In contrast,
we observed that endostatin significantly inhibited VEGF-
induced tube formation on collagen I (Fig. 9, circles).
Interestingly, it would appear that endostatin did not
interfere with the early stages of tube formation and cells
were able to align with one another, however their ability
to organize into tube structures with lumen was signifi-
cantly impaired. These data again support the notion that
the mechanisms by which TSP-1 and IP-10 inhibit
endothelial cells and angiogenesis are different than that
of endostatin. Furthermore, it would appear that the
mechanisms of inhibition induced by TSP-1 and IP-10 are
affected by growth of HDMEC on collagen I while
endostatin retains its ability to inhibit endothelial cell sur-
vival and organization in the presence of signals induced
by growth of cells on collagen I.
Discussion
We had previously observed that VEGF enhanced survival
of HDMEC grown on collagen I [31], suggesting that fac-
tors such as elevated collagen I levels within tumor micro-
environments could increase endothelial cell survival and
thus could potentially induce resistance to angiostatic
molecules in vivo. We decided to formally examine this
hypothesis and determined that growth on the tumor-
associated matrices collagen I and tenascin C impaired the
ability of TSP-1 and IP-10 to inhibit endothelial cell pro-
liferation and induce endothelial cell apoptosis (in the
case of collagen I). The ability of TSP-1 to inhibit endothe-
lial cell proliferation has previously been suggested to be
dependent on its ability to bind to heparin and compete
with heparin-binding growth factors for binding sites on
cells [41]. As TSP-1 has been previously shown to be able
to bind collagen I, it is quite possible that TSP-1 is seques-
tered from cells by binding collagen I, thus allowing the
heparin-binding growth factors to stimulate the prolifera-
tion of HDMEC on collagen I [42]. Thrombospondin has
also been previously shown to induce apoptosis in
endothelial cells via activation of caspase-3 [8,9]. Surpris-
ingly, although we did see a dose-dependent decrease in
the levels of procaspase-3 following treatment of HDMEC
on collagen I with TSP-1 in combination with VEGF, indi-
cating activation of caspase-3, this was not associated withBMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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the induction of significant apoptosis as compared to
stimulation with VEGF alone. Unlike other studies sug-
gesting that TSP-1 induced endothelial cell apoptosis in a
caspase-3 dependent manner [8,9], our studies were per-
formed in the presence of exogenous VEGF, thus although
some processing of caspase-3 occurs in response to TSP-1
in our experimental conditions, it is not enough to over-
come the survival effects induced by simultaneous exoge-
nous VEGF stimulation. Other studies have implicated
caspase-8, fas and fasL as the main mediators of TSP-1-
induced apoptosis [43]. We attempted to determine if cas-
pase-8 was playing a role in TSP-1-induced apoptosis in
our model system, however were unable to detect active
caspase-8 using western blot assays. There are a number of
differences between our study and those previously
reported, including different endothelial cell types that are
known to behave differently in experimental conditions
[44-46] and different TSP-1 concentrations than those
used in our studies. In fact, it was reported that when TSP-
1 was delivered in combination with 50 ng/ml of VEGF,
the cells became resistant to TSP-1 [43], thus confirming
our observations.
We also observed that growth on collagen I prevented the
angiostatic chemokine IP-10 from inhibiting endothelial
cell proliferation and inducing endothelial cell apoptosis.
The mechanisms of endothelial cell inhibition by IP-10
have not been extensively studied. Previous data has sug-
gested that IP-10 can inhibit endothelial cell proliferation
[47], however other reports suggest that IP-10 had no
effect on endothelial cell growth, attachment or migra-
tion, but did however inhibit bFGF-induced tube forma-
tion in vitro and in vivo [18]. More recently, using IP-10
mutants that have impaired binding domains, the angi-
ostatic activity of IP-10 was shown to be dependent on its
binding to the g-protein coupled receptor CXCR3 [48]. It
has been previously demonstrated that cell migration in
response to SDF-1 via activation of CXCR4 is enhanced in
the presence of fibronectin, suggesting that signaling
through integrins can affect the downstream signal trans-
duction pathway activated by the CXC receptors [49]. To
date, there are no studies implicating integrins in CXCR3
signaling, however the CXCR family of receptors are very
homologous so it is highly possible that ECM binding
through the integrins can modulate the response follow-
ing CXCR3 activation. As very little is known about the
mechanism by which IP-10 inhibits angiogenesis, further
investigation into the mechanism of inhibition of
endothelial cell proliferation and induction of apoptosis
by IP-10, and the effects of tumor-associated extracellular
matrices is warranted.
We also examined the ability of endostatin to inhibit
endothelial cell proliferation following growth on plastic,
collagen I, laminin or tenascin C. As seen with the other
inhibitors, endostatin was not able to inhibit endothelial
cell proliferation when HDMEC were cultured on colla-
gen I or tenascin C as a substrate. Previous data suggested
that inhibition of proliferation of endothelial cells is one
of the primary mechanisms of its anti-angiogenic capabil-
ities [22,24]. Subsequently, endostatin has been shown to
affect multiple facets of the angiogenic process including
cell migration [23,24], survival [50], protease activity
[51,52], and vessel stabilization [50,53]. Discrepancies in
the results obtained using endostatin can be observed
depending on the source of endostatin used in the exper-
iments, which can be either bacterially derived [24], puri-
fied from murine hemangioendothelioma cells [22], or
derived from Pichia pastoris. We have used the latter
source of endostatin for our studies, and it has previously
been shown to inhibit endothelial cell proliferation and
migration and to induce a G1 arrest in cells [54]. Our
observations support previous observations that endosta-
tin can inhibit VEGF-induced endothelial cell prolifera-
tion to some extent; however, we have extended these
findings to demonstrate that in the presence of the
"tumor-associated" ECM proteins collagen I and tenascin
C, this inhibition of proliferation by endostatin is dramat-
ically impaired. The receptor that binds endostatin to
inhibit angiogenic activities remains unclear despite
numerous studies indicating its ability to bind cell surface
molecules such as glypicans [55], heparin [56], tropomy-
osin-3 [57], VEGFR1 and VEGFR2 [58], and integrins αv
and  α5  [59]. It has been previously shown that α5β1
integrins cluster following endostatin binding [60], and
since collagen I and tenascin C can both bind β1 integrins
(in association with various α integrin chains) it is highly
possible that binding of these matrices by integrins could
modulate either the affinity for endostatin binding or
integrin signal transduction cascades through an inside-
out signal [61]. Furthermore, a peptide derived from
endostatin has recently been shown to be a potent inhib-
itor of angiogenesis in a β1 integrin and heparin-depend-
ent manner [62], suggesting that perhaps collagen I and
tenascin C compete with endostatin for integrin-binding
on cells and supporting our observations that endostatin
was ineffective at inhibiting endothelial cell proliferation
following growth on collagen I or tenascin C.
In contrast to our results with endothelial cell prolifera-
tion, we found that endostatin could induce apoptosis of
endothelial cells regardless of whether they were cultured
on plastic or collagen I substrates. In fact, we observed
endothelial cell apoptosis at doses 100-fold lower than
has previously been described [25]. The previous studies
indicated that endostatin's ability to induce apoptosis was
due to its ability to decrease bcl-2 expression and induce
activation of caspase-3 [25]. In contrast to these results,
we did not observe either a decrease in bcl-2 expression
nor activation of caspase-3 in HDMEC following endosta-BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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tin stimulation in either the presence or absence of VEGF.
In these studies, bovine pulmonary artery endothelial
cells were used, thus differences observed between the
doses of endostatin required to induce apoptosis could
again be a reflection of differences in the behavior of dif-
ferent endothelial cell types.
As endostatin has been previously shown to bind to a
number of different integrin molecules [59], and recently
it has been demonstrated that the inappropriate ligation
of integrins can lead to what has been referred to as
integrin-mediated death [63], it is possible that endosta-
tin may induce apoptosis via alternative mechanisms such
as integrin-mediated death. This form of apoptosis was
shown to be dependent on caspase-8, and our observation
of activation of caspase-8 observed at the higher doses of
endostatin supports the notion that the apoptosis
observed in our system following treatment with endosta-
tin may be related to integrin-mediated death. Recently, it
has also been shown that endostatin inhibited the migra-
tion on and attachment of endothelial cells to collagen I,
but did not affect the proliferation of endothelial cells cul-
tured on this matrix [64], which is in complete agreement
with our results. Other evidence would also suggest that
the main mechanism of inhibition of angiogenesis by
endostatin is via its ability to inhibit cell migration
through  α5β1 integrin, heparan sulfate, and lipid raft-
mediated interactions [65], supporting our observations
regarding endostatin's ability to inhibit vessel formation
in our tube formation assays, where endothelial cell
migration is a prerequisite for structure formation, and
our results would suggest that this effect is independent of
signals from collagen I.
In conclusion, we have demonstrated that TSP, IP-10 and
endostatin mediate inhibition of angiogenesis via differ-
ent mechanisms that are affected to different degrees by
growth of the endothelial cells on substrates such as colla-
gen I. Our data suggests that the biological effects that var-
ious angiostatic molecules have on endothelial cells may
be affected by the type of extracellular matrix upon which
the cells are in contact. Indeed, the importance of cues
from the extracellular matrix in vessel survival are also evi-
dent from transgenic animal systems where targeted dele-
tion of the collagen I gene in mice led to embryonic death,
due to rupture of blood vessels [66]. The effects of ECM on
vessel survival and angiogenesis is extremely important in
the context of inhibition of angiogenesis as an anti-tumor
therapy as tumors usually have extensively remodeled
matrix with differences in the composition of this matrix
as compared to that found in normal tissues. Given the
differences in the human tumor matrix microenviron-
ment, and our results that "tumor-associated" matrices
such as collagen I and tenascin C may enhance the resist-
ance of endothelial cells to certain anti-angiogenic agents,
it is imperative that we gain a clearer understanding of the
mechanism of inhibition of angiogenesis by these mole-
cules and how this may be affected by differences in the
tumor microenvironment. These insights will potentially
help to predict patient response to these inhibitors and
elucidate targets of intervention that will be unaffected by
differences in the tumor matrix microenvironment.
Methods
Endothelial cells and antibody reagents
Human dermal microvascular endothelial cells (HDMEC)
derived from neonatal tissue were obtained from Cam-
brex Corporation (Walkersville, MD) and were propa-
gated in EGM-2MV media (Cambrex Corp., Walkersville,
MD). All experiments were performed using cells between
passages 4 and 10. Rabbit anti-Bax and goat anti-Caspase-
3 antibodies were from R&D Systems (Minneapolis, MN).
Hamster anti-Bcl-2 antibody was purchased from BD
Pharmingen (Mississauga, ON) and rabbit anti-active cas-
pase-3 antibody was from Biovision (Palo Alto, CA).
Mouse anti-caspase-8 antibody was purchased Cell Sign-
aling Technologies (Beverly, MA).
Coating tissue culture dishes with collagen
Vitrogen 100 bovine dermal collagen (Cohesion Technol-
ogies, Palo Alto, CA) was used to coat tissue culture vessels
in all experiments, and is a mixture of ~97% collagen I
and ~3% collagen III matrices. The acidified collagen
solution was kept on ice, diluted to a concentration of 1.5
mg/ml, and neutralized following addition of 10× PBS
and 0.1 N NaOH to a pH of approximately 7.4. The
appropriate volume of collagen solution was added to
coat each vessel and the plates were rocked to ensure even
distribution of collagen across the surface. Plates were
then incubated at 37°C for 4 h to overnight to allow gela-
tion to occur. The collagen surfaces were washed with
Hanks Buffered Salt Solution (HBSS, Invitrogen,
Carlsbad, CA), and incubated in EGM-2MV for a mini-
mum of 2 h to equilibrate the collagen prior to addition
of endothelial cells. For coating with laminin, human pla-
centa laminin (Sigma, Oakville, ON) was diluted in PBS
and added to dishes at a concentration of 1 µg/cm2. The
dishes were allowed to dry overnight, uncovered, in a lam-
inar-flow hood and cells were seeded on the surfaces the
next day. For tenascin C, dishes were coated with tenascin
C purified from a human tumor cell line (Chemicon Inter-
national, Temecula, CA). For coating, tenascin-C was
diluted to 0.1 µg/ml in PBS, and added to dishes which
were then incubated overnight at 4°C. The next day, the
solution was aspirated, and the dishes were blocked with
0.1% casein solution for at least 1 h. The dishes were then
washed three times with 1× PBS, and seeded with cells.BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
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Proliferation assays
HDMEC were seeded at a density of 15,000 cells per well
in EGM-2MV into untreated or matrix coated 12-well
plates as described above and allowed to incubate over-
night. The next day, media was removed, cells were
washed twice with HBSS and then starved overnight in
MCDB 131 (Invitrogen, Carlsbad, CA) containing 1%
fetal bovine serum (FBS). The following day cells were
stimulated with varying concentrations of either TSP-1
(Calbiochem, San Diego, CA), IP-10 (Intergen, Purchase,
NY), or endostatin (Calbiochem, San Diego, CA) together
with 50 ng/ml VEGF (kind gift from the Biological
Resources Branch of the National Cancer Institute) in
MCDB 131 containing 5% FBS. Stimulation with 50 ng/
ml VEGF in MCDB 131 containing 5% FBS was used as a
positive control for proliferation, and stimulation with
MCDB 131 containing only 1% FBS was used as a negative
control for proliferation. Following 72 h of incubation,
cells were collected by trypsinization or by collagenase
treatment in the case of cells seeded on collagen substrate,
and the number of cells per unit volume in each well was
determined following counting in a Coulter counter. Each
treatment was performed in triplicate and the entire exper-
iment was performed a minimum of three independent
times.
BrdU Cell Proliferation ELISA
HDMEC were seeded at a density of 2,500 cells per well in
EGM-2MV into untreated or collagen I coated 96-well
plates as described above and allowed to incubate over-
night. The next day, media was removed, cells were
washed twice with HBSS and then starved overnight in
MCDB 131 containing 1% FBS. The following day cells
were stimulated with varying concentrations of either
TSP-1, IP-10, or endostatin together with 50 ng/ml VEGF
in MCDB 131 containing 5% FBS. BrdU labeling solution
was subsequently added 48 h post-stimulation with
growth factors and inhibitors, and cells were incubated
overnight. Incorporated BrdU was subsequently detected
using the BrdU Cell Proliferation ELISA, kit according to
the manufacturers directions (Roche, Laval, PQ), using a
Fluoroskan Ascent Plate reader (Thermolabs, Franklin,
MA) for luminescent detection.
Determination of apoptosis by FACS
HDMEC were seeded into untreated or collagen I coated
dishes and allowed to adhere overnight. The following
day, monolayers were washed with HBSS to remove non-
adherent cells, and adherent cells were stimulated with
MCDB 131 media containing 5% FBS (unstimulated), or
MCDB 131 media with 5% FBS supplemented with 50 ng/
ml VEGF alone, 10, 50 or 250 ng/ml TSP-1, 16, 80 or 400
ng/ml IP-10, or 100, 500 or 2500 ng/ml endostatin alone
or in combination with 50 ng/ml VEGF. Cells were incu-
bated for 60 h, and then harvested by collecting the non-
adherent and adherent cell populations either by trypsini-
zation or collagenase treatment for plastic and collagen I
coated dishes respectively. Collected cells were pelleted by
centrifugation at 300 × g, washed twice with PBS, and then
resuspended in ice-cold 70% ethanol. Cell suspensions
were incubated in 70% ethanol at -20°C for a minimum
of 24 h. Following permeabilization, cells were washed
two times with PBS, and then resuspended in 500 ul of
propidium iodide solution (48 ug/ml propidium iodide,
40 ug/ml Rnase A in PBS). The percentage of apoptotic
cells was determined following identification of the sub-
G1 population of cells by flow cytometric analysis.
Detection of caspase-3 or caspase-8 activity
HDMEC were seeded into untreated or collagen I coated
dishes and allowed to adhere overnight. The following
day, monolayers were washed with HBSS to remove non-
adherent cells, and cells were stimulated with EGM-2MV
media alone, 50 ng/ml VEGF alone, or 50 ng/ml TSP-1, 80
ng/ml IP-10, or 500 ng/ml endostatin alone or in combi-
nation with 50 ng/ml VEGF in EGM-2MV. Cells were
incubated for 48 h, and then harvested by collecting the
non-adherent and adherent cell population by either
trypsinization or collagenase treatment for plastic and col-
lagen I coated dishes respectively. Collected cells were pel-
leted by centrifugation at 300 × g, washed with PBS,
counted and then stored at -80°C. At time of assay, cells
were lysed in the appropriate volume of lysis buffer (10
mM HEPES, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl,
142.5 mM KCl, and 1 mM DTT) so that equal cell
number/unit volume was obtained for each sample. Sam-
ples were incubated on ice for 45 minutes followed by a
centrifugation at 13,000 rpm at 4°C for 30 minutes in a
microfuge. Supernatants were removed and 20 ul of each
sample was added to assay buffer (50 mM HEPES, 1 mM
EDTA, 100 mM NaCl, 10% glycerol, 0.1% CHAPS, 10 mM
DTT, pH 7.4) in a 96-well microtiter plate. Plates were
allowed to equilibrate at 37°C for 10 minutes, and then
10 ul of a 1 mM stock of the fluorogenic caspase-3 sub-
strate Ac-DEVD-AMC (Alexis Biochemicals, San Diego,
CA) was added to each well. Plates were incubated at
37°C to allow the enzymatic reaction to proceed, and the
fluorescence was measured at various times post-addition
of substrate using a fluorescent plate reader set at 460 nm
emission/360 nm excitation wavelengths. Purified cas-
pase-3 was used as a positive control in all assays, and all
samples were assayed in triplicate. Experiments were per-
formed a minimum of three independent times.
For detection of caspase-8 activity, cells were seeded into
dishes and stimulated as described above. Following incu-
bation for 48 h, cells were isolated following trypsiniza-
tion, washed once with PBS, and cell pellets were stored at
-80°C. Subsequently, the pellets were lysed in provided
caspase activity lysis buffer according to the manufac-BMC Cell Biology 2005, 6:38 http://www.biomedcentral.com/1471-2121/6/38
Page 18 of 20
(page number not for citation purposes)
turer's directions (Sigma, Oakville, ON), the protein con-
centration for each lysate was determined, and caspase-8
activity was determined according to the manufacturer,
using a fluorogenic caspase-8 activity kit (Sigma, Oakville,
ON) that used Ac-IETD-AMC as a substrate and fluoro-
metric detection in a fluorescent plate reader set at 460
nm emission/360 nm excitation wavelengths.
Western blot analysis
HDMEC were seeded on plastic or collagen I coated dishes
as described above and allowed to adhere overnight. The
next day, monolayers were washed twice with HBSS and
then stimulated with varying concentrations of TSP-1, IP-
10 or endostatin alone or in combination with 50 ng/ml
VEGF. Total protein lysates were generated in boiling lysis
buffer (1% SDS, 1.0 mM sodium ortho-vanadate, 10 mM
Tris pH 7.4, 0.2 mM PMSF, 2 µg/ml aprotinin) following
recovery of cells from dishes by trypsinization or colla-
genase treatment for growth on plastic or collagen I
respectively. Aliquots containing 5–40 µg of total protein
were subjected to SDS-PAGE electrophoresis followed by
transfer to nitrocellulose membranes. Specific proteins
were detected following incubation with primary and
horse-radish peroxidase-conjugated secondary antibodies
and visualization using chemiluminescent detection
(Supersignal, Pierce, Rockford, MD).
Endothelial cell sprouting assays
Collagen I gels were prepared as described above. 2 × 105
HDMEC were seeded onto each 60 mm dish of collagen I
and allowed to adhere overnight. The following day the
dishes were washed twice with HBSS and then stimulated
with EGM-2MV alone or supplemented with 50 ng/ml
VEGF alone or in combination with 50 ng/ml TSP, 80 ng/
ml IP-10 or 500 ng/ml endostatin. Cells were counted on
day 0 prior to stimulation to ensure similar numbers of
cells had been seeded on each dish, and were then
counted daily for 12 days. Media containing supplements
was replaced every 48 hours.
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